AKBA Q2 2024 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$44M-22.6% YoY

Gross Profit

$35M81.0% margin

Operating Income

-$9M-20.0% margin

Net Income

-$9M-19.7% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

+33.9%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$220M

Total Liabilities

$254M

Stockholders' Equity

-$34M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44M	$56M	-22.6%
Gross Profit	$35M	$39M	-9.6%
Operating Income	-$9M	-$9M	+3.0%
Net Income	-$9M	-$11M	+23.2%

Revenue Segments

Product

$41M94%

License Collaboration And Other Revenue

$2M6%